Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Phleum pratense allergen extract** is a standardized allergen extract derived from the pollen of *Phleum pratense* (Timothy grass), used in allergen immunotherapy to induce immune tolerance and reduce symptoms of allergic rhinitis and conjunctivitis due to grass pollen allergy. It is administered as a sublingual tablet (SLIT) or as a subcutaneous injection as part of an allergen-specific immunotherapy regimen. The extract contains a mixture of major and minor Timothy grass pollen proteins standardized for consistent potency. Its immunological action includes induction of allergen-specific blocking IgG4 antibodies, modulation of regulatory T-cells, and a shift away from the Th2-mediated allergic response, leading to long-term tolerance and symptom reduction. Primary indications are the treatment and prophylaxis of grass pollen-induced seasonal allergic rhinitis and conjunctivitis in patients with documented sensitization[^1][^3][^8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phleum pratense allergen extract.